Overview
The Human PD-L1 inhibitor III is a highly specialized peptide designed to target the programmed cell death 1 (PD-1) receptor and its ligand, PD-L1. This interaction forms a critical immune checkpoint that plays a vital role in downregulating T cell activation. Many cancer cells overexpress PD-L1 to evade immune surveillance, which is where our PD-L1 inhibitor comes into play. By binding to human PD-1, this peptide effectively inhibits the PD-1/PD-L1 interaction, making it an essential tool in cancer research and therapy development.
Key Features
- Targets the PD-1/PD-L1 checkpoint
- Contains specific anchor residues for enhanced binding
- Available in 1 mg unit size
- Supports research in immunotherapy and cancer treatment
- High purity and reliable performance
Specifications
| Product Name | Human PD-L1 Inhibitor III |
| Unit Size | 1 mg |
| Category | Peptides |
| CAS Number | [Add CAS Number] |
FAQ
What is the function of the Human PD-L1 inhibitor III?
This peptide works by binding to the human PD-1 receptor to block its interaction with PD-L1, thereby potentially enhancing T cell activation against cancer cells.
How is the Human PD-L1 inhibitor III used in research?
It’s primarily utilized in studies focused on immunotherapy, cancer research, and understanding immune checkpoint mechanisms.
Can the Human PD-L1 inhibitor III be used in clinical settings?
While primarily for research use, data gleaned from its application may influence future therapeutic strategies against cancers that exploit the PD-1/PD-L1 pathway.
If you’re interested in advanced therapeutic research, consider adding the Human PD-L1 inhibitor III to your lab’s toolkit. Explore more about our other peptides, such as Autocamtide-2 or CREBtideto enhance your experimental designs. Shop now and bring high-quality research solutions to your projects!
Related Products
Browse more in Peptides.




Reviews
There are no reviews yet.